People: Cellmid Ltd (CDY.AX)

CDY.AX on Australia Stock Exchange

0.02AUD
12 Feb 2016
Change (% chg)

$0.00 (+5.26%)
Prev Close
$0.02
Open
$0.02
Day's High
$0.02
Day's Low
$0.02
Volume
130,133
Avg. Vol
1,062,213
52-wk High
$0.04
52-wk Low
$0.02

Search Stocks

Summary

Name Age Since Current Position

David King

2008 Independent Non-Executive Chairman of the Board

Maria Halasz

2007 Chief Executive Officer, Managing Director, Executive Director

Aliceson Rourke

2015 Chief Financial Officer, Company Secretary

Nicholas Falzon

2015 Financial Controller

Bruce Gordon

2015 Non-Executive Director

Edward Walton

2015 Non-Executive Director

Biographies

Name Description

David King

Dr. David William King , Ph.D., has been Independent Non-Executive Chairman of the Board of Cellmid Ltd since January 18, 2008. He is Fellow of The Australian Institute of Company Directors, Fellow of the Australian Institute of Geoscientists and holds a Doctorate in Philosophy in Seismology from the Australian National University in 1974. He also obtained a Bachelor of Science in Physics from University of East Anglia in 1968 and a Master of Science in Geophysics from University of London in 1969. He is Member of the Audit Committee, and Remuneration Committee. He is Director of Robust Resources Limited and Republic Gold Limited and was Director of Gas2Grid Limited, Ausmon Resources Limited, Sapex Limited and Eastern Star Gas Limited.

Maria Halasz

Ms. Maria Halasz has been Chief Executive Officer, Managing Director and Executive Director of Cellmid Ltd since April 16, 2007. She is a Graduate of the Australian Institute of Company Directors and holds a Bachelor of Science degree in Microbiology and a Masters of Business Administration from University of Western Australia. She has over 18 years of experience in biotechnology companies; initially working in executive positions in biotechnology firms, then managing investment funds and later holding senior positions in corporate finance specializing in life sciences.

Aliceson Rourke

Nicholas Falzon

Mr. Nicholas Falzon has been Financial Controller of Cellmid Ltd. He has resigned from the position of Joint Company Secretary of the Company with effect from 31 March 2015. As a partner at Lawler Partners, he works with a number of listed and unlisted companies advising them on all aspects of their financial management. He holds a Bachelor of Business at UTS and is a member of the Institute of Chartered Accountants of Australia.

Bruce Gordon

Mr. Bruce Gordon is Non-Executive Director of the Company., effective 1 July 2015. Mr Bruce Gordon, who will be joining the Board on 1 July 2015, has over 25 years of audit and finance experience in industries such as retail, healthcare, resources and manufacturing. After a distinguished career as Senior Audit Partner, in his most recent role he was Partner in Charge of BDO Australia’s National Corporate Finance Team. Significantly, Bruce has had a long association with Cellmid through his roles at BDO and has a thorough understanding of the Company’s operations, including both the midkine and the consumer health businesses. He brings considerable international corporate finance experience to his role as non-executive director of Cellmid, in addition to his deep knowledge of the Company.

Edward Walton

Dr. Edward Fintan Walton has been appointed as Non-Executive Director of Cellmid Limited., with effect from 21 July 2015. He is Founder and CEO of PharmaVentures Ltd, a UK based corporate advisory firm with more than 30 professional advisers, assisting pharmaceutical and biotechnology companies worldwide in all aspects of corporate transactions, business brokering, mergers and acquisitions and licensing deals. Since he founded PharmaVentures in 1992, he and his team have advised blue chip clients in North America, Europe and Asia, delivering more than 700 assignments for 180 companies in 38 countries. Dr Walton has worked with clients including most of the major and mid-sized pharmaceutical and biotechnology companies. His experience extends to industries such as pharmacetuicals, diversified chemicals, diagnostics, medical devices, generic and over-the-counter medicines as well as government agencies. He has transactional experience representing corporates as well as major banks, investment and merchant banks, private equity and venture capital groups. Educated at Trinity College (Dublin, Ireland), where he obtained his PhD in genetics, Dr Walton has subsequently gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992) prior to founding PharmaVentures.

Basic Compensation

Name Fiscal Year Total

David King

70,999

Maria Halasz

514,268

Aliceson Rourke

--

Nicholas Falzon

--

Bruce Gordon

--

Edward Walton

--
As Of  29 Jun 2014

Options Compensation

Search Stocks